"Biological Availability" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action.
| Descriptor ID |
D001682
|
| MeSH Number(s) |
G03.787.151 G07.690.725.129
|
| Concept/Terms |
Biological Availability- Biological Availability
- Availability, Biological
- Availabilities, Biological
- Biological Availabilities
- Biologic Availability
- Physiologic Availability
- Availability, Biologic
- Availabilities, Biologic
- Biologic Availabilities
- Bioavailability
- Bioavailabilities
- Availability, Physiologic
- Availabilities, Physiologic
- Physiologic Availabilities
Availability Equivalency- Availability Equivalency
- Availability Equivalencies
- Equivalencies, Availability
- Equivalency, Availability
|
Below are MeSH descriptors whose meaning is more general than "Biological Availability".
Below are MeSH descriptors whose meaning is more specific than "Biological Availability".
This graph shows the total number of publications written about "Biological Availability" by people in this website by year, and whether "Biological Availability" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 4 | 5 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 6 | 6 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 9 | 9 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 7 | 7 |
| 2018 | 0 | 5 | 5 |
| 2019 | 1 | 4 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Availability" by people in Profiles.
-
Controlled API-polymer solidification (CAPS): A novel manufacturing process approach to produce amorphous solid dispersion with enhanced physical properties. J Pharm Sci. 2026 Jan; 115(1):104028.
-
Silymarin nanocrystals-laden chondroitin sulphate-based thermoreversible hydrogels; A promising approach for bioavailability enhancement. Int J Biol Macromol. 2022 Oct 01; 218:456-472.
-
Age-and Region-Dependent Disposition of Raloxifene in Rats. Pharm Res. 2021 Aug; 38(8):1357-1367.
-
Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021 Sep 10; 204:114255.
-
Enhanced solubility and biopharmaceutical performance of atorvastatin and metformin via electrospun polyvinylpyrrolidone-hyaluronic acid composite nanoparticles. Eur J Pharm Sci. 2021 Jun 01; 161:105817.
-
Pegylated arginine deiminase depletes plasma arginine but maintains tissue arginine availability in young pigs. Am J Physiol Endocrinol Metab. 2021 03 01; 320(3):E641-E652.
-
Piroxicam loaded polymer hybrid microspheres based tablets with modified release kinetics: Development, characterization and in vivo evaluation. Pak J Pharm Sci. 2021 Jan; 34(1(Supplementary)):327-335.
-
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020 12; 86(6):829-840.
-
Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. Ther Drug Monit. 2020 10; 42(5):679-685.
-
Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability. Pharmacotherapy. 2020 07; 40(7):704-712.